Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | EDNRB | P24530 | 6/20 | 0.56 |
| ▸ | EDNRA | P25101 | 6/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21465521 | 0.96 | MEN1 (0.93) | MEN1KMT2ACYP3A4MAPTALOX15 | |
| SCHEMBL29465029 | 0.96 | MEN1 (0.93) | MEN1KMT2ACYP3A4MAPTALOX15 | |
| SCHEMBL21465631 | 0.95 | MEN1 (0.91) | MEN1KMT2ACYP3A4MAPTALOX15 | |
| SCHEMBL25761849 | 0.93 | MEN1 (0.87) | MEN1KMT2ACYP3A4MAPTALOX15 | |
| SCHEMBL21465481 | 0.92 | MAPT (0.85) | MEN1KMT2ACYP3A4MAPTALOX15 | |
| SCHEMBL21465486 | 0.91 | MEN1 (0.83) | MEN1KMT2ACYP3A4MAPTALOX15 | |
| SCHEMBL25761854 | 0.91 | MEN1 (0.83) | MEN1KMT2ACYP3A4MAPTALOX15 | |
| SCHEMBL21465553 | 0.91 | MEN1 (0.83) | MEN1KMT2ACYP3A4MAPTALOX15 | |
| SCHEMBL21465466 | 0.91 | MEN1 (0.83) | MEN1KMT2ACYP3A4MAPTALOX15 | |
| SCHEMBL21465533 | 0.90 | MEN1 (0.82) | MEN1KMT2ACYP3A4MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-06-24 | — | — | US | claimed |
| US-20240398905-A1 | COMPOSITIONS AND METHOD FOR ADMINISTERING PPARgamma AGONISTS, SURFACTANT PEPTIDES AND PHOSOPHOLIPIDS | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 2024-12-05 | — | — | US | claimed |
| US-11951158-B2 | Compositions and methods for administering PPARγ agonists, surfactant peptides and phospholipids | LINDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER (US) | 2024-04-09 | — | — | US | claimed |
| US-20230172919-A1 | AN INSULIN SENSITIZER FOR USE IN THE PREVENTION AND/OR TREATMENT OF THE DAMAGES CAUSED BY RETINAL DETACHMENT | SORBONNE UNIVERSITE (FR) | 2023-06-08 | — | — | US | claimed |
| US-20230043587-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-02-09 | — | — | US | claimed |
| EP-4125838-A1 | AN INSULIN SENSITIZER FOR USE IN THE PREVENTION AND/OR TREATMENT OF THE DAMAGES CAUSED BY RETINAL DETACHMENT | SORBONNE UNIVERSITE (FR) | 2023-02-08 | — | — | EP | claimed |
| US-20220324796-A1 | ANTIBIOTIC COMPOUNDS | EMORY UNIVERSITY | 2022-10-13 | — | — | US | claimed |
| US-20220142985-A1 | AGENTS FOR TREATMENT OF ALCOHOL USE DISORDER | SERVICIO ANDALUZ DE SALUD (ES) | 2022-05-12 | — | — | US | claimed |
| US-20260078161-A1 | METHODS OF USING ACTIVIN RECEPTOR TYPE II VARIANTS | KEROS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-06-24 | — | — | US | disclosed |
| EP-4531879-A1 | COMPOSITIONS OF SECRETORY AND/OR CATALYTIC CELLS AND METHODS USING THE SAME | Flagship Pioneering Innovations VI, LLC (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-114729311-B | Preparation method of brown adipocytes | 株式会社片冈制作所 | 2025-02-18 | — | — | CN | disclosed |
| EP-3733203-A1 | PROPHYLACTIC AGENT AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICINAL COMPOSITION FOR PREVENTING AND/OR TREATING CATARACT, USE OF PPAR ACTIVATOR FOR PRODUCING SAME, AND EYEDROPS | University of Fukui (JP) | 2020-11-04 | — | — | EP | disclosed |
| CN-111511402-A | Agent for preventing and/or treating cataract, pharmaceutical composition for preventing and/or treating cataract, use of PPAR activator for producing the same, and eye drop | 国立大学法人福井大学 | 2020-08-07 | — | — | CN | disclosed |
| WO-2019199979-A1 | ANTIBACTERIAL COMPOUNDS | THE GENERAL HOSPITAL CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019199979-A1 | ANTIBACTERIAL COMPOUNDS | THE GENERAL HOSPITAL CORPORATION (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20150004144-A1 | DIFFERENTIATION INTO BROWN ADIPOCYTES | THE GENERAL HOSPITAL CORPORATION (US) | 2015-01-01 | — | — | US | disclosed |
| US-20040235019-A1 | Solid phase synthesis; drug screening; diabetes; obesity | AGOURON PHARMACEUTICALS, INC. | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043587-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASE | COL2A1, ALPI, COL14A1 | MEN1 947/4885KMT2A 3677/4885CYP3A4 4287/4885 |
| US-20260078161-A1 | METHODS OF USING ACTIVIN RECEPTOR TYPE II VARIANTS | ACVR2A, ACVRL1, ACVR2B | MEN1 1515/4885KMT2A 2771/4885CYP3A4 3323/4885 |
| US-12337023-B2 | Methods and compositions for the prevention and treatment of disease | COL2A1, ALPI, COL14A1 | MEN1 947/4885KMT2A 3677/4885CYP3A4 4287/4885 |
| US-20220324796-A1 | ANTIBIOTIC COMPOUNDS | NRDC, MMP8, CLPP | MEN1 3319/4885KMT2A 3808/4885CYP3A4 2864/4885 |
| US-20220142985-A1 | AGENTS FOR TREATMENT OF ALCOHOL USE DISORDER | ADH1A, ADH5, ADH1C | MEN1 4875/4885KMT2A 1365/4885CYP3A4 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.